Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 806.60M | 736.09M | 728.22M | 689.49M | 573.89M |
Gross Profit | 91.10M | 241.09M | 622.42M | 577.87M | 481.03M |
EBITDA | 144.85M | 144.63M | 141.82M | 131.64M | 108.17M |
Net Income | 21.82M | 23.41M | 25.81M | 23.51M | 7.81M |
Balance Sheet | |||||
Total Assets | 1.54B | 1.51B | 1.51B | 1.53B | 1.50B |
Cash, Cash Equivalents and Short-Term Investments | 75.06M | 77.17M | 101.98M | 152.12M | 121.39M |
Total Debt | 876.44M | 887.67M | 911.55M | 1.00B | 971.50M |
Total Liabilities | 1.21B | 1.20B | 1.21B | 1.31B | 1.30B |
Stockholders Equity | 313.81M | 299.24M | 289.33M | 216.09M | 188.65M |
Cash Flow | |||||
Free Cash Flow | 71.24M | 84.56M | 89.86M | 65.98M | 132.74M |
Operating Cash Flow | 82.06M | 97.50M | 103.20M | 79.92M | 146.50M |
Investing Cash Flow | -23.93M | -15.69M | -41.99M | -27.65M | -205.94M |
Financing Cash Flow | -60.22M | -106.69M | -110.88M | -21.53M | 40.24M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | €268.84M | 12.09 | 7.12% | 30.23% | 9.58% | -6.69% | |
52 Neutral | $7.47B | -0.04 | -63.86% | 2.34% | 16.17% | 0.25% | |
― | €1.80B | ― | -0.83% | ― | ― | ― | |
― | €1.78B | 0.02 | -22.82% | ― | ― | ― | |
― | €778.06M | 21.53 | 16.07% | 2.41% | ― | ― | |
― | €1.19B | ― | -6.74% | ― | ― | ― | |
42 Neutral | €73.68M | ― | ― | 44.34% | -27.37% |
LNA Santé reported strong financial results for 2024, meeting its targets despite challenges in the healthcare sector. The company achieved a 6.7% increase in operating sales and a 7.7% rise in net operating profit, while managing its debt effectively. The company plans to continue its growth trajectory in 2025, targeting a 6% increase in operating sales and focusing on strategic acquisitions and facility transformations to meet healthcare demands.